Spain experiencing a resurgence of Covid-19 cases but not yet a second wave
During the first wave of the Covid-19 pandemic in March, Spain was one of the most heavily affected countries in…
Read More…
Focus:
Europe
-
![transthyretin amyloidosis]()
Morphosys/Incyte’s Monjuvi becomes first approved therapy for relapsed and refractory DLBCL in second-line treatment setting
Treatment of diffuse large B-cell lymphoma (DLBCL), the most common type of B-cell non-Hodgkin’s lymphoma, had seen a major transformation…
Read More…
-
![Ovid Angelini Angelman syndrome]()
Ovid and Angelini partner on treating Angelman syndrome in Europe
US-based Ovid’s Angelman syndrome drug OV101 is currently in the late stages of a Phase...
Read More...
-
![abiomed]()
Abiomed’s Impella receives FDA Emergency Use Authorization during Covid-19 pandemic
On 4 August, Abiomed announced that the FDA had issued an Emergency Use Authorization (EUA) for their left-sided Impella heart…
Read More…
-
![Sanofi; Depakine]()
Sanofi faces formal investigation over epilepsy drug Depakine
Healthcare company Sanofi Aventis France is facing formal investigation regarding charges of manslaughter over epilepsy...
Read More...
-
![Numab Boehringer antibody]()
Numab and Boehringer Ingelheim partner on multi-specific antibody therapies
Numab and Boehringer Ingelheim have teamed up to discover multi-specific antibody-based drugs for lung and...
Read More...
-
![BioCardia]()
BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure
BioCardia is resuming its Phase III CardiAMP Heart Failure (HF) trial for its stem cell therapy regimen, CardiAMP, after halting…
Read More…
-
![personalised medicine Rozlytrek]()
Roche’s Rozlytrek gets EC approval to treat solid tumours and NSCLC
Roche has received conditional marketing approval from the European Commission (EC) for Rozlytrek (entrectinib) to...
Read More...
-
![Celltrion]()
Celltrion drug Remsima SC has potential to erode Remicade shares
On 27 July, the European Commission (EC) granted marketing authorisation for the first subcutaneous (SC) formulation of Celltrion drug Remsima…
Read More…
-
![abicipar pegol]()
Side effect profile of Allergan’s abicipar pegol is a roadblock to penetrating the wAMD Market
In May 2020, AbbVie’s $63B acquisition of Allergan became the largest merger since Bristol-Myers Squibb acquired Celgene for $74B at…
Read More…
